Drugs / FAP allogeneic immunosuppressive CAR-DC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07380659 | Jan 2026 → Jan 2027 expected | ST-elevation myocardial infarction, cardiogenic shock | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAP allogeneic immunosuppressive CAR-DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07380659 ↗ |
| Known as | iCDC | “engineered a stable, immunosuppressive, and fibrotic lesion-targeted DC therapy, termed immunosuppressive DCs (iCDC).” NCT07380659 ↗ |
| Modality | Cell therapy | “FAP immunosuppressive CAR-DC cell therapy” NCT07380659 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT07380659 ↗ |
| Target | FAP | “FAP-targeted immunosuppressive iCDC therapy” NCT07380659 ↗ |